| DB ID | MyCo_2563 |
| Title | Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis |
| Year | 2012 |
| PMID | 22825124 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | A previously described cell culture model of the human alveolus containing an air-liquid interface was used. Briefly, this model consists of a cellular bilayer con- structed of human pulmonary artery endothelial cells (HPAECs) (Lonza Biologics, Slough, United Kingdom) and human alveolar epithelial cells (A549; LGC Standards, Teddington, United Kingdom) on opposing sides of the polyester membrane of a Transwell insert (Corning Life Sciences, Lowell, MA). The cellular bilayer delineates an air-filled alveolar compartment (above the cellular bilayer) and the fluid-filled endothelial compartment (below the cellular bilayer), which mimics the pulmonary vasculature. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | voriconazole MIC, 0.5 mg/liter, triazole(MICs, 4 to 16 mg/liter), |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is a frequent cause of death in immunocompromised patients. Voriconazole is a first- line treatment, but there are increasing reports of triazole resis- tance in Aspergillus fumigatus, which is associated with increased mortality. Other therapeutic options for IPA include lipid formulations of amphotericin B and the echinocandins. However, the echinocandins are not fungicidal in laboratory ani- mal models and are associated with relatively poor outcomes for profoundly immunocompromised patients. Fur- thermore, the use of all formulations of amphotericin B may be limited by infusional toxicity and nephrotoxicity, which may be detrimental to patient outcomes. Further insights into poten- tially effective regimens for treatment of triazole-resistant isolates are urgently required. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | double-sandwich enzyme-linked immunosorbent assay (ELISA) (Platelia Aspergillus kit; Bio-Rad, Hemel Hempstead, United Kingdom) |
| Assay Data | None |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
